Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Emerging Therapies | Venclexta (venetoclax) | US | Wave 2 | 2017

Login to access report north_east
Contact sales account_box

Venclexta (Wave 2) is the second in a multiwave series designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic lymphocytic leukemia (CLL) drug, Venclexta (Roche/AbbVie’s venetoclax). Launch Tracking Venclexta measures the impact of this novel agent on the relapsed/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. This content evaluates physicians’ current awareness and perception of Venclexta relative to other currently available therapies for relapsed/refractory CLL, current and anticipated use of Venclexta, and promotional activity of Venclexta.

Questions answered:

  • What are the awareness of and familiarity with Venclexta among hematologist-oncologists?
  • What are the perceived clinical advantages and disadvantages of Venclexta compared with other marketed agents used for treating relapsed/refractory CLL?
  • To what extent is Venclexta currently being used by surveyed hematologist-oncologists? Where does Venclexta fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Venclexta?
  • What promotional messages are being employed by Roche/AbbVie?

Scope:

Market covered: United States.

Primary research: 75 hematologist-oncologists; qualitative interviews with 10 respondents.

Indication coverage: Relapsed/refractory CLL.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
north_east
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
north_east
Report
Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…
north_east
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east